TR199902437T2 - Monofosforil lipid A'ya ait sulu imünolojik adjuvant terkipleri. - Google Patents

Monofosforil lipid A'ya ait sulu imünolojik adjuvant terkipleri.

Info

Publication number
TR199902437T2
TR199902437T2 TR1999/02437T TR9902437T TR199902437T2 TR 199902437 T2 TR199902437 T2 TR 199902437T2 TR 1999/02437 T TR1999/02437 T TR 1999/02437T TR 9902437 T TR9902437 T TR 9902437T TR 199902437 T2 TR199902437 T2 TR 199902437T2
Authority
TR
Turkey
Prior art keywords
surfactant
lipid
derivative
diluted
monophosphoryl lipid
Prior art date
Application number
TR1999/02437T
Other languages
English (en)
Inventor
R. Crane Thomas
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of TR199902437T2 publication Critical patent/TR199902437T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Seyreltilmis bir lipid A türevi ve bir surfaktan veya sicak kanli bir hayvanda protein antijenine bagisikligi saglayan surfaktanlar ihtiva eden sulu bir ilaç bilesimi. Bu bulusa göre faydali olan seyreltilmis lipid A türevleri monoforforik lipid A ve 3-0-deasilatli monofosforik lipid A içerir. Surfaktan veya surfaktan bilesimleri bir solvent içinde çözünür. 1,2-dipalmitoil-an-glisero-3-forfokolin tercih edilen surfaktandir. Çözünen surfaktan seyreltilmis lipid A türevine bir karisim elde etmek üzere ilave edilir. Seyreltilen lipid A türevinin karisiminda surfaktantin mol orani 4:12dir. Solvent evapore edilir ve sonuçta çikan tabakaya su ilave edilir. Süspansiyon 60 C su banyosunda berraklasincaya kadar sonikatlanir.
TR1999/02437T 1997-04-01 1998-04-01 Monofosforil lipid A'ya ait sulu imünolojik adjuvant terkipleri. TR199902437T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83107397A 1997-04-01 1997-04-01

Publications (1)

Publication Number Publication Date
TR199902437T2 true TR199902437T2 (tr) 2000-01-21

Family

ID=25258229

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02437T TR199902437T2 (tr) 1997-04-01 1998-04-01 Monofosforil lipid A'ya ait sulu imünolojik adjuvant terkipleri.

Country Status (18)

Country Link
EP (1) EP0971739B1 (tr)
JP (1) JP5019494B2 (tr)
KR (1) KR100603884B1 (tr)
CN (2) CN1326564C (tr)
AT (1) ATE278419T1 (tr)
AU (1) AU743114B2 (tr)
BR (1) BR9811262A (tr)
CA (1) CA2284586C (tr)
DE (1) DE69826842T2 (tr)
ES (1) ES2227825T3 (tr)
HU (1) HUP0001403A3 (tr)
IL (2) IL132126A0 (tr)
NO (1) NO994760L (tr)
NZ (1) NZ338101A (tr)
PL (1) PL190237B1 (tr)
PT (1) PT971739E (tr)
TR (1) TR199902437T2 (tr)
WO (1) WO1998043670A2 (tr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
PT1889630E (pt) 2000-10-18 2012-02-29 Glaxosmithkline Biolog Sa Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CN101203605B (zh) * 2004-12-17 2016-01-27 由卫生福利和体育大臣代表的荷兰王国 革兰氏阴性菌的lps的脱酰基化
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
ATE526036T1 (de) * 2005-08-02 2011-10-15 Novartis Vaccines & Diagnostic Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8018440B2 (en) 2005-12-30 2011-09-13 Microsoft Corporation Unintentional touch rejection
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US8836648B2 (en) 2009-05-27 2014-09-16 Microsoft Corporation Touch pull-in gesture
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
FR2954703B1 (fr) 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US8261213B2 (en) 2010-01-28 2012-09-04 Microsoft Corporation Brush, carbon-copy, and fill gestures
US9411504B2 (en) 2010-01-28 2016-08-09 Microsoft Technology Licensing, Llc Copy and staple gestures
US9519356B2 (en) 2010-02-04 2016-12-13 Microsoft Technology Licensing, Llc Link gestures
US8799827B2 (en) 2010-02-19 2014-08-05 Microsoft Corporation Page manipulations using on and off-screen gestures
US9310994B2 (en) 2010-02-19 2016-04-12 Microsoft Technology Licensing, Llc Use of bezel as an input mechanism
US9367205B2 (en) 2010-02-19 2016-06-14 Microsoft Technolgoy Licensing, Llc Radial menus with bezel gestures
US8751970B2 (en) 2010-02-25 2014-06-10 Microsoft Corporation Multi-screen synchronous slide gesture
US8707174B2 (en) 2010-02-25 2014-04-22 Microsoft Corporation Multi-screen hold and page-flip gesture
US9454304B2 (en) 2010-02-25 2016-09-27 Microsoft Technology Licensing, Llc Multi-screen dual tap gesture
US9075522B2 (en) 2010-02-25 2015-07-07 Microsoft Technology Licensing, Llc Multi-screen bookmark hold gesture
US8689123B2 (en) 2010-12-23 2014-04-01 Microsoft Corporation Application reporting in an application-selectable user interface
US8612874B2 (en) 2010-12-23 2013-12-17 Microsoft Corporation Presenting an application change through a tile
US9423951B2 (en) 2010-12-31 2016-08-23 Microsoft Technology Licensing, Llc Content-based snap point
US9383917B2 (en) 2011-03-28 2016-07-05 Microsoft Technology Licensing, Llc Predictive tiling
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9658766B2 (en) 2011-05-27 2017-05-23 Microsoft Technology Licensing, Llc Edge gesture
US9104307B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9158445B2 (en) 2011-05-27 2015-10-13 Microsoft Technology Licensing, Llc Managing an immersive interface in a multi-application immersive environment
US9104440B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9557909B2 (en) 2011-09-09 2017-01-31 Microsoft Technology Licensing, Llc Semantic zoom linguistic helpers
US9146670B2 (en) 2011-09-10 2015-09-29 Microsoft Technology Licensing, Llc Progressively indicating new content in an application-selectable user interface
US9244802B2 (en) 2011-09-10 2016-01-26 Microsoft Technology Licensing, Llc Resource user interface
WO2013038185A1 (en) 2011-09-12 2013-03-21 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
US9582122B2 (en) 2012-11-12 2017-02-28 Microsoft Technology Licensing, Llc Touch-sensitive bezel techniques
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9477337B2 (en) 2014-03-14 2016-10-25 Microsoft Technology Licensing, Llc Conductive trace routing for display and bezel sensors
BE1022857A1 (fr) * 2014-03-26 2016-09-27 Glaxosmithkline Biologicals Sa Immunisation contre staphylococcus aureus
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
IL308201A (en) 2020-09-17 2024-01-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
EP4346896A4 (en) * 2021-05-27 2025-04-02 Revelation Biosciences, Inc. Mpla compositions and methods of use
CN121221758B (zh) * 2025-12-02 2026-03-03 华诺泰生物医药科技(成都)有限公司 一种即用型稳定3d-mla佐剂溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen

Also Published As

Publication number Publication date
CA2284586C (en) 2011-02-08
ATE278419T1 (de) 2004-10-15
NZ338101A (en) 2002-03-28
NO994760D0 (no) 1999-09-30
PL190237B1 (pl) 2005-11-30
IL132126A0 (en) 2001-03-19
HUP0001403A2 (hu) 2000-09-28
NO994760L (no) 1999-11-26
DE69826842D1 (de) 2004-11-11
CN1575815A (zh) 2005-02-09
JP2001526640A (ja) 2001-12-18
CA2284586A1 (en) 1998-10-08
AU6947398A (en) 1998-10-22
PT971739E (pt) 2004-12-31
CN1326564C (zh) 2007-07-18
HUP0001403A3 (en) 2003-05-28
KR100603884B1 (ko) 2006-07-24
EP0971739A2 (en) 2000-01-19
IL132126A (en) 2006-10-05
KR20010005882A (ko) 2001-01-15
DE69826842T2 (de) 2005-11-24
WO1998043670A3 (en) 1998-12-30
WO1998043670A2 (en) 1998-10-08
CN1259052A (zh) 2000-07-05
JP5019494B2 (ja) 2012-09-05
EP0971739B1 (en) 2004-10-06
BR9811262A (pt) 2000-10-17
AU743114B2 (en) 2002-01-17
ES2227825T3 (es) 2005-04-01
HK1026613A1 (en) 2000-12-22
PL336698A1 (en) 2000-07-03

Similar Documents

Publication Publication Date Title
TR199902437T2 (tr) Monofosforil lipid A'ya ait sulu imünolojik adjuvant terkipleri.
ATE381344T1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
BR0010323A (pt) Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
DK0978282T3 (da) Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
PT3078667T (pt) Formulação de compostos de ácido borónico
ES539266A0 (es) Un procedimiento para la preparacion de nuevas-n-heterociclil-4-piperidinaminas.
NO961377D0 (no) Distamycin A-analoger som antitumor eller antivirale midler
ES2177178T3 (es) Procedimiento mejorado para la obtencion de precursores de insulina con puentes cistina correctamente unidos.
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
HUT44390A (en) Aqueous microemulsion concentrates
MX9302169A (es) Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales.
MY117606A (en) Orally administrable formulations of quinolone- or naphthyridonecarboxylic acids
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
BR9813810B1 (pt) surfactante baseado em um orto éster, a sua preparação e o seu uso.
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
ATE192735T1 (de) Verfahren zur herstellung von aminoxyd tenside enthaltenden festen zusammensetzungen
ATE274570T1 (de) Pumpfähige wässrige zusammensetzungen mit hohem feststoffgehalt und hohem anteil an monoalkylphosphatestersalz
EE03087B1 (et) Adenosiini derivaadid, nende valmistamise meetodid ja neid sisaldavad ravimvormid
BR9408571A (pt) Composições sólidas contendo sais de ácido maléico e óxido de amina
DK236884A (da) 2-alkyl-4-(3',5'-di(pseudo)halogen-phen-4'-on)-indonaphth-1-oler samt fremgangsmaade til deres fremstilling
ES2186191T3 (es) Productos de reaccion del acido fosfonico y su uso en composiciones de recubrimiento.
TR199903159T2 (tr) Yeni -Amino ve -Azido karbonik asit türevleri.
TR200001760T1 (tr) Sınıf III antiarritmik bileşim içeren ispençiyari müstahzar
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri